Fungitell STAT® Assay

Single Sample Format For Rapid Invasive Fungal Infection (IFI) Screening.


Fungitell® Assay

The Gold Standard in Rapid Screening For Invasive Fungal Infection (IFI).


Beacon Diagnostics® Laboratory

Serving clinical and reference laboratories, we offer a rapid, cost-effective alternative to in-house testing.

Fungal Trends & Statistics

Invasive fungal infection: More aggressive medical care, including immunosuppressive therapy and ICU care has greatly increased the population of patients at risk of invasive fungal infection (IFI). There are an estimated 40-60 thousand invasive fungal infections in the USA annually. Candidemia represents the 4th leading cause of nosocomial blood stream infection and the 3rd most common ICU bloodstream infection.

The low sensitivity and relatively long incubation times of microbial culture, the most widely used diagnostic technique, has resulted in a need for faster methods with greater sensitivity. With its high sensitivity, high negative predictive value, and rapid availability of results, the use of Fungitell® has increased steadily since its clearance by the FDA in 2004.

Early diagnosis and treatment have been shown to have increased survival rates in Candidal Shock.

Why Test For (1→3)-β-D-Glucan

Most pathogenic fungi* have (1→3)-β-D-Glucan in their cell walls and minute, but detectable quantities are released into the circulation during infection. Detection of elevated levels of (1→3)-β-D-Glucan is an aid to the presumptive diagnosis of invasive fungal infection (IFI) in at risk patients.


Fungitell®, an FDA cleared and CE marked diagnostic test, is used for the detection of (1→3)-β-D-Glucan, which is frequently associated with the presence of fungal pathogens. The majority of these are Candida and Aspergillus species.

Rapid Screening For Invasive Fungal Infection